Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres

被引:36
作者
Polin, RS
Marko, NF
Ammerman, MD
Shaffrey, ME
Huang, W
Anderson, FA
Caputy, AJ
Laws, ER
机构
[1] George Washington Univ, Sch Med, Dept Neurosurg, Washington, DC 20037 USA
[2] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA
[3] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA
关键词
glioma; dominant hemisphere; nondominant hemisphere; prognostic factor; outcome; case management;
D O I
10.3171/jns.2005.102.2.0276
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. The goal of this study was to investigate survival and functional outcomes in patients with high-grade intracranial astrocytomas as a function of the location of the lesion in the dominant or nondominant hemisphere (DH and NDH, respectively), and to suggest management strategies for such patients based on these data. Methods. Data were collected from the Glioma Outcomes Project database, a longitudinal database of demographic, clinical, and outcome data for patients with high-grade intracranial gliomas. From the entire database of 788 patients, a subset of all 280 tight-handed patients with newly diagnosed, unilateral gliomas involving potentially eloquent cortex was selected as the sample population. Two cohorts were defined based on the location of the tumor in the right or left cerebral hemisphere. All other relevant demographic and clinical data were nearly identical between the cohorts. A KaplanMeier analysis was conducted to assess survival, and Kamofsky Performance Scale scores assigned at 6 and 12 months postoperatively were compared as a measure of functional outcome. The analysis demonstrated no difference in survival between patients with lesions in the DH and those with tumors in the NDH. Additionally, no statistically significant difference in functional outcomes was observed between the two groups.Conclusions. Laterality of high-grade gliomas is not an independent prognostic factor for predicting survival or functional outcome. The findings in this study demonstrate that fears of increased postoperative morbidity or mortality in otherwise resectable tumors of the DH are unfounded, and the authors therefore advocate that the surgeon's decision to operate be guided by validated outcome predictors and not biased by tumor lateralization.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 50 条
  • [21] Druggable genomic landscapes of high-grade gliomas
    Ghanem, Paola
    Fatteh, Maria
    Kamson, David Olayinka
    Balan, Archana
    Chang, Michael
    Tao, Jessica
    Blakeley, Jaishri
    Canzoniero, Jenna
    Grossman, Stuart A.
    Marrone, Kristen
    Schreck, Karisa C.
    Anagnostou, Valsamo
    FRONTIERS IN MEDICINE, 2023, 10
  • [22] Venous thromboembolism and survival in patients with high-grade glioma
    Simanek, Ralph
    Vormittag, Rainer
    Hassler, Marco
    Roessler, Karl
    Schwarz, Martin
    Zielinski, Christoph
    Pabinger, Ingrid
    Marosi, Christine
    NEURO-ONCOLOGY, 2007, 9 (02) : 89 - 95
  • [23] Mifepristone Repurposing in Treatment of High-Grade Gliomas
    Llaguno-Munive, Monserrat
    Vazquez-Lopez, Maria Ines
    Jurado, Rafael
    Garcia-Lopez, Patricia
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Using Magnetic Resonance Perfusion to Stratify Overall Survival in Treated High-Grade Gliomas
    Fong, Crystal
    Parpia, Sameer
    Yemen, Brian
    Tsai, Scott
    Greenspoon, Jeffrey
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2019, 46 (05) : 533 - 539
  • [25] Monoclonal antibodies in diagnostics of high-grade gliomas
    Baklaushev V.P.
    Pavlov K.A.
    Chekhonin V.P.
    Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2009, 3 (2) : 105 - 115
  • [26] Dendritic cell vaccines for high-grade gliomas
    Eagles, Matthew E.
    Nassiri, Farshad
    Badhiwala, Jetan H.
    Suppiah, Suganth
    Almenawer, Saleh A.
    Zadeh, Gelareh
    Aldape, Kenneth D.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1299 - 1313
  • [27] Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan
    Nongnuch Sirachainan
    Atthaporn Boongird
    Thiti Swangsilpa
    Wipawi Klaisuban
    Apasri Lusawat
    Suradej Hongeng
    Child's Nervous System, 2017, 33 : 893 - 897
  • [28] Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan
    Sirachainan, Nongnuch
    Boongird, Atthaporn
    Swangsilpa, Thiti
    Klaisuban, Wipawi
    Lusawat, Apasri
    Hongeng, Suradej
    CHILDS NERVOUS SYSTEM, 2017, 33 (06) : 893 - 897
  • [29] Radiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas
    Gregucci, Fabiana
    Surgo, Alessia
    Carbonara, Roberta
    Laera, Letizia
    Ciliberti, Maria Paola
    Gentile, Maria Annunziata
    Caliandro, Morena
    Sasso, Nicola
    Bonaparte, Ilaria
    Fanelli, Vincenzo
    Tortora, Romina
    Paulicelli, Eleonora
    Surico, Giammarco
    Lombardi, Giuseppe
    Signorelli, Francesco
    Fiorentino, Alba
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (08):
  • [30] Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas
    Kline, Cassie N.
    Joseph, Nancy M.
    Grenert, James P.
    van Ziffle, Jessica
    Yeh, Iwei
    Bastian, Boris C.
    Mueller, Sabine
    Solomon, David A.
    NEURO-ONCOLOGY, 2016, 18 (05) : 752 - 753